Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

Anja Lachenmayer, Sara Toffanin, Laia Cabellos, Clara Alsinet, Yujin Hoshida, Augusto Villanueva, Beatriz Minguez, Hung Wen Tsai, Stephen C. Ward, Swan Thung, Scott L. Friedman, Josep M. Llovet

Research output: Contribution to journalArticle

115 Scopus citations

Abstract

Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown. We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclinical models of liver cancer. Methods: Gene expression and copy number changes were analyzed in a cohort of 334 human HCCs, while the effects of panobinostat and sorafenib were evaluated in three liver cancer cell lines and a murine xenograft model. Results: Aberrant HDAC expression was identified and validated in 91 and 243 HCCs, respectively. Upregulation of HDAC3 and HDAC5 mRNAs was significantly correlated with DNA copy number gains. Inhibiting HDACs with panobinostat led to strong anti-tumoral effects in vitro and vivo, enhanced by the addition of sorafenib. Cell viability and proliferation declined, while apoptosis and autophagy increased. Panobinostat increased histone H3 and HSP90 acetylation, downregulated BIRC5 (survivin) and upregulated CDH1. Combination therapy with panobinostat and sorafenib significantly decreased vessel density, and most significantly decreased tumor volume and increased survival in HCC xenografts. Conclusions: Aberrant expression of several HDACs and copy number gains of HDAC3 and HDAC5 occur in HCC. Treatment with panobinostat combined with sorafenib demonstrated the highest preclinical efficacy in HCC models, providing the rationale for clinical studies with this novel combination.

Original languageEnglish (US)
Pages (from-to)1343-1350
Number of pages8
JournalJournal of Hepatology
Volume56
Issue number6
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Keywords

  • Hepatocellular carcinoma
  • Histone modification
  • Liver cancer
  • Molecular therapies
  • Signaling pathways

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib'. Together they form a unique fingerprint.

  • Cite this

    Lachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., Villanueva, A., Minguez, B., Tsai, H. W., Ward, S. C., Thung, S., Friedman, S. L., & Llovet, J. M. (2012). Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Journal of Hepatology, 56(6), 1343-1350. https://doi.org/10.1016/j.jhep.2012.01.009